Thomas Stankovich

Thomas Stankovich, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in ReShape Lifesciences Inc., Response Genetics Inc and Cobalis Corp. In total, 66 filings cover trades dated from 9 January 2005 to 31 May 2024.

The open-market side counts 23 purchases for €181k alongside 37 sales for €245k. Sales outweigh purchases by €65k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants. So far in 2024, the count stands at no purchases and 4 sales.

Half of the purchases are above €985 and half below. 2 out of 14 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 9 purchases show a median change of +0.7%, with the price up in 100% of them. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 13 August 2024 with an open-market sale (€9) in ReShape Lifesciences Inc. The last purchase on record was published on 6 July 2023, which is 1,206 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 6 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.